MENU
+Compare
RNAZ
Stock ticker: NASDAQ
AS OF
Jul 14, 02:18 PM (EDT)
Price
$8.77
Change
+$0.08 (+0.92%)
Capitalization
7.24M

RNAZ TransCode Therapeutics Inc Forecast, Technical & Fundamental Analysis

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer... Show more

RNAZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RNAZ with price predictions
Jul 11, 2025

RNAZ in upward trend: 10-day moving average broke above 50-day moving average on July 11, 2025

The 10-day moving average for RNAZ crossed bullishly above the 50-day moving average on July 11, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 20, 2025. You may want to consider a long position or call options on RNAZ as a result. In of 62 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

RNAZ moved above its 50-day moving average on July 08, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAZ advanced for three days, in of 163 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 51 cases where RNAZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 28 cases where RNAZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RNAZ broke above its upper Bollinger Band on July 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.703) is normal, around the industry mean (17.292). P/E Ratio (0.001) is within average values for comparable stocks, (58.926). RNAZ's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.456). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (272.270).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RNAZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RNAZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
6 Liberty Square
Phone
+1 857 837-3099
Employees
10
Web
https://www.transcodetherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LGO1.380.05
+3.76%
Largo
TALO9.130.27
+3.05%
Talos Energy
INDP12.34N/A
N/A
Indaptus Therapeutics Inc
NWS34.29-0.16
-0.46%
News Corp
MLR45.03-0.53
-1.16%
Miller Industries

RNAZ and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAZ has been loosely correlated with NGNE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RNAZ jumps, then NGNE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAZ
1D Price
Change %
RNAZ100%
-3.50%
NGNE - RNAZ
48%
Loosely correlated
-2.41%
ABCZF - RNAZ
37%
Loosely correlated
N/A
BPTSY - RNAZ
33%
Poorly correlated
-8.28%
AGEN - RNAZ
32%
Poorly correlated
+19.26%
JAGX - RNAZ
31%
Poorly correlated
+2.66%
More